Synthaverse Balance Sheet Health

Financial Health criteria checks 2/6

Synthaverse has a total shareholder equity of PLN113.6M and total debt of PLN78.9M, which brings its debt-to-equity ratio to 69.4%. Its total assets and total liabilities are PLN293.2M and PLN179.6M respectively. Synthaverse's EBIT is PLN5.8M making its interest coverage ratio 3.1. It has cash and short-term investments of PLN743.0K.

Key information

69.4%

Debt to equity ratio

zł78.88m

Debt

Interest coverage ratio3.1x
Cashzł743.00k
Equityzł113.63m
Total liabilitieszł179.59m
Total assetszł293.22m

Recent financial health updates

Recent updates

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Financial Position Analysis

Short Term Liabilities: SVE's short term assets (PLN44.1M) exceed its short term liabilities (PLN43.8M).

Long Term Liabilities: SVE's short term assets (PLN44.1M) do not cover its long term liabilities (PLN135.8M).


Debt to Equity History and Analysis

Debt Level: SVE's net debt to equity ratio (68.8%) is considered high.

Reducing Debt: SVE's debt to equity ratio has increased from 28.8% to 69.4% over the past 5 years.

Debt Coverage: SVE's debt is not well covered by operating cash flow (8%).

Interest Coverage: SVE's interest payments on its debt are well covered by EBIT (3.1x coverage).


Balance Sheet


Discover healthy companies